LNSR
LENSAR, Inc.·Healthcare
5.70
4.396%(+0.24)
Market ClosedLast Updated: — ET
52W L: $5.3352W H: $14.31
LNSR NEWS
seekingalpha.com
Mar 31
LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript
LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 31
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025
defenseworld.net
Mar 28
Contrasting DexCom (NASDAQ:DXCM) and LENSAR (NASDAQ:LNSR)
DexCom (NASDAQ: DXCM - Get Free Report) and LENSAR (NASDAQ: LNSR - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Volatility and Risk DexCom has a beta of 1.48, suggesting
benzinga.com
Mar 17
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review
In March 2025, Alcon agreed to acquire the laser solutions company for $14.00 per share for an aggregate implied value of approximately $356 million.
gurufocus.com
Mar 17
BYND And LNSR Set The Tone Tuesday
Beyond Meat (BYND) and LENSAR (LNSR) are among the names driving early action Tuesday as stock futures edge lower and oil prices move higher amid ongoing Iran r
globenewswire.com
Mar 16
LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC (“Alcon”) to terminate the merger agreement between the parties.
